ENGN
enGene Holdings Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.82
−0.55%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 369.0K | — | — | — | — |
| Gross Profit | (369.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 98.7M | 94.5M | 38.3M | 16.5M | 15.5M |
| SG&A Expense | 35.4M | 28.7M | 24.0M | 8.5M | 3.3M |
| General & Admin Expense | 35.4M | 28.7M | 24.0M | 8.5M | 3.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.8M) | — | — | 1.1M | 700.0K |
| Total Operating Expenses | 132.4M | 123.2M | 62.3M | 26.1M | 19.4M |
| Cost and Expenses | 132.6M | 123.2M | 62.3M | 26.1M | 19.4M |
| Operating Income (EBIT) | (68.6M) | (123.2M) | (62.3M) | (26.1M) | (19.4M) |
| Non-Operating | |||||
| Interest Income | 4.3M | 9.4M | 10.4M | 1.1M | 129.0K |
| Interest Expense | 3.0M | 3.0M | 2.8M | 5.0M | 1.4M |
| Net Interest Income | 6.6M | 6.4M | 7.6M | (3.8M) | (1.3M) |
| Other Non-Op Income/Expense | 2.0M | 5.9M | 7.1M | (73.8M) | (5.0M) |
| Non-Operating Income (excl Interest) | 58.0M | (8.9M) | (9.9M) | 68.9M | 3.6M |
| EBT (Pre-Tax Income) | (66.7M) | (117.3M) | (55.2M) | (99.9M) | (24.4M) |
| Income Tax Expense | (258.0K) | — | (19.0K) | 17.0K | 22.0K |
| Bottom Line | |||||
| Net Income | (66.4M) | (117.3M) | (55.1M) | (99.9M) | (24.5M) |
| Earnings from Cont. Ops | (66.4M) | (117.3M) | (55.1M) | (99.9M) | (24.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (66.4M) | (117.3M) | (55.1M) | (104.7M) | (29.0M) |
| Per Share | |||||
| Basic EPS | ($1.32) | ($2.29) | ($1.46) | ($4.24) | ($1.84) |
| Diluted EPS | ($1.32) | ($2.29) | ($1.46) | ($4.24) | ($1.84) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 69.7M | 51.1M | 44.6M | 23.6M | 15.8M |
| Diluted Shares Outstanding | 69.7M | 51.1M | 44.6M | 23.6M | 15.8M |
| Profitability Metrics | |||||
| EBITDA | (125.9M) | (113.8M) | (52.0M) | (94.8M) | (22.8M) |
| D&A | 670.0K | 509.0K | 323.0K | 175.0K | 238.0K |
| EBIT | (126.6M) | (114.3M) | (52.4M) | (94.9M) | (23.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Apr 1, 2026